Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology (NANOPI)

11. září 2015 aktualizováno: Centre Hospitalier Universitaire de Saint Etienne

Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology. A Monocentric Study

Nanoparticles (NP) are particles whose length, width and height are less than 100 nanometres. Over the past decade, industrial applications of NP have increased dramatically. Despite their widespread use, their true impact on human health remains unknown and poorly studied. NP exposure in humans primarily occurs via inhalation through the respiratory system. The aim of this study is to estimate the relationships between the nanoparticle load in the lung and bronchi and some interstitial lung diseases. In the aftermath of human exposure to asbestos, the pathological consequences of environmental exposure to nanomaterials could be evaluated upon a mineralogical analysis of pulmonary samples.

Přehled studie

Postavení

Dokončeno

Podmínky

Intersticiální plicní onemocnění

Intervence / Léčba

Typ studie

Pozorovací

Zápis (Aktuální)

100

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

Francie
- - Saint-Etienne, Francie, 42055
    - CHU Saint-Etienne

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Ukázka pravděpodobnosti

Studijní populace

" Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.
" Control group ": patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.

Popis

Inclusion Criteria:

Patients with an interstitial lung disease assessed on clinical signs and CT scan, requiring a flexible bronchoscopy with a broncho-alveolar lavage.

These patients suffer from:

Idiopathic interstitial lung diseases such as idiopathic pulmonary fibrosis or sarcoidosis OR
Interstitial lung diseases of known aetiologies such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.

Written consent

Exclusion Criteria:

Flexible bronchoscopy or BAL not possible.
Pregnant women
Patients under legal protection.
Patients with contagious disease (HIV infection, tuberculosis, viral hepatitis)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Počet skupin / kohort

Kohorty a intervence

Skupina / kohorta	Intervence / Léčba
Idiopathic interstitial diseases " Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis. Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.	Jiný: BAL Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: BW Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: EAC Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: blood specimen Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: Urine specimen Patients with idiopathic and non idiopathic interstitial lung diseases
Non idiopathic intertitial diseases " Control group ": patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions. Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.	Jiný: BAL Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: BW Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: EAC Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: blood specimen Patients with idiopathic and non idiopathic interstitial lung diseases Jiný: Urine specimen Patients with idiopathic and non idiopathic interstitial lung diseases

Skupina / kohorta

Intervence / Léčba

Idiopathic interstitial diseases

" Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.

Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.

Jiný: BAL